Bulk Inquiry
TUG 891
Axon 2075
CAS:
1374516-07-0
Purity:
99%
- Soluble in DMSO
- MF: C23H21FO3
- MW: 364.41
Description
TUG 891 is a potent and selective GPR120/FFA4 agonist with reported EC50 values of 44 nM for human GPR120 and 17 nM for mouse GPR120. It activates free fatty acid receptor signaling linked to metabolic and inflammatory regulation.
GPR120/FFA4 responds to long-chain fatty acids and regulates incretin secretion, insulin sensitivity, macrophage inflammation and lipid metabolism. TUG 891 is useful for studying FFA4-selective GPCR pharmacology in metabolic and immunometabolic models.
Key Features
- Selective GPR120/FFA4 agonist
- Reported EC50: 44 nM human and 17 nM mouse GPR120
- Activates fatty acid-responsive GPCR signaling
- Relevant to metabolic inflammation and incretin research
Applications
- GPR120 receptor assays
- Free fatty acid signaling studies
- Metabolic disease model research
- Immunometabolic pathway pharmacology
More Information
| Parent CAS No. | 1374516-07-0 |
|---|---|
| Chemical Name | 3-(4-((4-fluoro-4'-methylbiphenyl-2-yl)methoxy)phenyl)propanoic acid |
| SMILES | C1(CCC(O)=O)=CC=C(OCC2=CC(F)=CC=C2C2=CC=C(C)C=C2)C=C1 |
| MFCD | N.A. |
| InChi | InChI=1S/C23H21FO3/c1-16-2-7-18(8-3-16)22-12-9-20(24)14-19(22)15-27-21-10-4-17(5-11-21)6-13-23(25)26/h2-5,7-12,14H,6,13,15H2,1H3,(H,25,26) |
| InChiKey | LPGBXHWIQNZEJB-UHFFFAOYSA-N |
| CID | 57522038 |
| Short Description | GPR120 agonist |
References
- DE Jorenby et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296 (1), 56–63.
- RS Obach et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006, 34, 121-30.
Other Categories
Get a Quote for
Loading...